Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetics

Clin Pharmacokinet. 1982 Jul-Aug;7(4):363-72. doi: 10.2165/00003088-198207040-00006.

Abstract

The pharmacokinetics of glipizide were studied in 6 type 2 diabetics following single dose intravenous administration of Img, and oral administration of 2.5 mg as a solution, a 2.5 mg tablet and a 5 mg tablet. The serum concentrations of the drug were measured by high pressure liquid chromatography. Glipizide showed a rapid distribution fitting a 2-compartment model. The distribution volume at assumed distribution equilibrium was small (10L), and the elimination half-life was short (2 to 4 hours). Gastrointestinal bioavailability was 100%. In one patient, glipizide absorption from tablets was retarded due to delayed tablet disintegration and drug dissolution. Each dose of glipizide reduced blood glucose levels rapidly in all patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biological Availability
  • Blood Glucose / metabolism
  • Diabetes Mellitus / blood
  • Diabetes Mellitus / drug therapy*
  • Female
  • Glipizide / blood
  • Glipizide / therapeutic use*
  • Humans
  • Kinetics
  • Male
  • Middle Aged
  • Sulfonylurea Compounds / therapeutic use*

Substances

  • Blood Glucose
  • Sulfonylurea Compounds
  • Glipizide